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EDITORIAL   
Adverse Cardiovascular Events with 
Nonsteroidal Anti-inflammatory Agents   
Antonis S. Manolis, MD 
Athens University School of Medicine, Athens, Greece  
ABSTRACT 
The extensive use of nonsteroidal anti-inflammatory 
drugs (NSAIDs), both nonselective and cyclooxygenase- 
2–specific inhibitors, for the relief of acute and chronic 
musculoskeletal pain, in addition to gastrointestinal 
toxicity, confers serious cardiovascular toxicity that affects 
the overall risk/benefit ratio of this commonly employed 
therapy. A plethora of studies have provided convincing 
evidence for a high risk of adverse cardiovascular events 
associated with NSAIDs related to a number of risk 
factors, which are herein briefly reviewed and an algorithm 
is suggested for their safer use. (Rhythmos 2015;10(2):21-27)  
Key Words: nonsteroidal anti-inflammatory drugs; coxibs; 
osteoarthritis; rheumatoid arthritis; cardiovascular disease; 
hypertension; myocardial infarction; heart failure  
Abbreviations: COX = cyclooxygenase; CV = cardiovascular; 
GI = gastrointestinal; MACE = major adverse cardiac events; 
MI = myocardial infarction; NSAIDs = non-steroidal anti-
inflammatory drugs PPI = proton pump inhibitor   
INTRODUCTION 
Nonsteroidal anti-inflammatory drugs (NSAIDs) 
comprise nonselective and cyclooxygenase (COX)-2–
specific inhibitors (Table 1), which are extensively used 
for the relief of acute and chronic pain associated with 
several medical conditions, like rheumatoid arthritis and 
osteoarthritis.1 Their use will most likely increase as the 
prevalence of osteoarthritis increases because of increased 
expected longevity of the population. However, in a 
plethora of clinical trials, serious adverse cardiovascular 
(CV) events have been reported with NSAID use,2-10 which 
constitutes an issue of public health importance that 
physicians should be aware of and guided by when 
prescribing these agents, especially in older individuals1 
who also have an increased prevalence of CV disease, or 
generally in patients with preexisting medical conditions.11  
Nonselective NSAIDs, like ibuprofen and naproxen, 
inhibiting both COX-1 and COX-2, have been available 
since the seventies, while the newer selective 
cyclooxygenase-2 (COX-2) inhibitor drugs (the coxibs), 
like valdecoxib, rofecoxib and celecoxib, were introduced 
decades later (end of nineties).12  
With regards to CV adverse effects of NSAIDs, the data 
are quite worrisome,2,4,7,10,13 although some studies have 
produced mixed results.5,12,14,15 COX-2 inhibitors have 
been found to induce myocardial infarction (MI) and 
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strokes, which have led to the withdrawal of rofecoxib and 
valdecoxib.3,6 The Alzheimer’s Disease Anti-
inflammatory Prevention (ADAPT) trial was discontinued, 
in part because of an excess of CV events noted with 
naproxen.16 On the other hand, pooled data from 13 trials 
with 7718 participants showed that nonselective NSAIDs 
had no significant effect on CV events (odds ratio-OR 
1.3).12 No significant effect was seen for joint disease trials 
(OR 0.6) or Alzheimer disease trials (OR 1.6).12 There was 
no significant difference in results for naproxen and non-
naproxen NSAIDs.  
Table 1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)  
Non-Selective   Selective COX-2 Inhibitors   
Salicylic Acid Derivatives   ● Celecoxib 
● Aspirin    ● Etoricoxib 
● Sulfasalazine    ● Lumiracoxib * 
Par-aminophenol Derivatives  ● Valdecoxib ** 
● Acetaminophen (Paracetamol)  ● Rofecoxib ** 
Indole and Indene Acetic Acids  ● Parecoxib 
● Indomethacin 
● Sulindac 
● Etodolac 
Heteroaryl Acetic Acids 
● Diclofenac 
● Ketorolac 
Arylpropionic Acids 
● Ibuprofen 
● Ketoprofen 
● Naproxen    
● Fenoprofen 
● Fluriprofen 
● Loxoprofen 
Anthranilic Acids (Fenamates) 
● Mefanamic acid 
Enolic Acids 
● Oxicams  
(Piroxicam/Meloxicam) 
Sulfonanilides 
● Nimesulide  
________________________________________ 
* Not available due to serious hepatotoxicity 
** Rofecoxib and valdecoxib have been withdrawn from the market 
N.B.: Celecoxib is currently the only COX-2 inhibitor available in the 
United States17   
The cardiotoxicity associated with use of NSAIDs may 
be attributed to increase in blood pressure, inhibition of 
prostacyclin synthesis, oxidative stress, and impaired 
endothelial function (Table 2). Both selective and 
nonselective NSAIDs inhibit COX-2-mediated 
prostaglandin E2 production, thus producing their 
analgesic and anti-inflammatory effects. 12 Inhibition of 
COX-1 by nonselective NSAIDs reduces the platelet 
aggregating factor thromboxane, which may have a 
cardioprotective effect as has been found with low-dose 
aspirin. Gastrointestinal (GI) toxicity is mitigated with use 
of COX-2 inhibitors compared with nonselective NSAIDs 
as COX-1-mediated cytoprotection is maintained. On the 
other hand, COX-2 inhibitors may have an adverse athero-
thrombotic profile, due to unopposed thromboxane 
synthesis and platelet aggregation. Furthermore, both 
nonselective and COX-2–selective NSAIDs have been 
associated with an increased incidence of hospitalization 
for congestive heart failure and high blood pressure.10, 17   
Table 2. Factors Conferring Cardiovascular Risk by 
NSAIDs  
● Hypertensive effect or impaired response to antihypertensive 
therapy (retention of sodium, increased renal vascular 
constriction, microvascular dysfunction) 
● Vascular disruption of COX-2 leading to depressed expression 
of endothelial nitric oxide synthase and consequent release and 
function of nitric oxide 
● Impaired endothelial function  
● Interaction with aspirin (interference with the antiplatelet 
effects of aspirin) 
● Prothrombotic effect of COX-2 inhibition, e.g. decreased 
production of the vasodilator prostacyclin (which also inhibits 
platelet activation) with concomitant unimpeded COX-1–
mediated production of platelet thromboxane A2 
● Disruption of COX-2 dependence of hemodynamic stability 
and renal function 
● Oxidative stress   
NONSELECTIVE NONSTEROIDAL ANTI-
INFLAMMATORY DRUGS 
An increase in arterial blood pressure is seen within 
weeks of starting treatment with a NSAID.6 However, the 
magnitude of the hypertensive response varies from drug 
to drug within this class. For example, naproxen exerts 
minimal vasopressor effect, whereas blood pressure rises 
consistently during treatment with diclofenac. The 
impression is that the blood pressure rise secondary to 
NSAIDs is dose dependent, but there are few dose-
response clinical trials reporting effects on blood pressure. 
Most studies of the hypertensive response to NSAIDs have 
focused on the role of the kidneys, because NSAIDs cause 
sodium retention and interfere with the action of 
antihypertensive drugs.6 In general, the available evidence 
suggests that the increase in CV risk of NSAIDs is 
commensurate with their hypertensive effect; however, 
interplay with several other factors may be equally 
important.  
An initial analysis of the REACH Registry was limited 
to 23,728 European patients (aged 67.2±9.8 years).8 A total 
of 20,588 (86.8%) had established atherothrombotic 
disease and 3140 (13.2%) had multiple risk factors only. 
At baseline, 1573 patients (6.6%) received NSAIDs and 
15,395 (64.9%) received aspirin. Among the 22,028 
(92.8%) with complete 2-year follow-up, 683 (3.2%) died 
from CV causes, while 395 (1.9%) had MI, 665 (3.1%) 
23 
 
stroke, 1651 (7.6%) cardiac major adverse CV events 
(MACE) (defined as the composite of CV death, MI or 
stroke) and 199 (1%) bleeding. NSAID use was 
independently associated with an increased risk of stroke 
(odds ratio-OR 1.635; p<0.001), and a trend towards an 
increased bleeding rate (OR 1.554; p=0.07). No asso-
ciation was found between NSAID use and MI or MACE. 
The authors concluded that NSAID use in stable patients 
with established atherothrombotic disease or multiple risk 
factors is independently associated with a 64% increase in 
stroke rates at 2 years, whereas no significant effect was 
observed on CV death or non-fatal MI.  
However, a more recent analysis from the same 
Registry, albeit of the entire registry population, 
comprising 44,095 patients showed different results about 
the use of NSAID over 4 years of follow-up.10 NSAID use 
was associated with an increased hazard for MI (hazard 
ratio - HR 1.37; P = 0.002), stroke (HR 1.21; P = 0.048), 
heart failure hospitalizations (HR 1.18; P = 0.013), and 
ischemic hospitalizations (HR 1.17; P = 0.001) or 
combined end-points (CV death/MI/ stroke/ ischemic 
hospitalizations, HR 1.12, P = 0.003; CV death/MI/ stroke, 
HR 1.16, P = 0.02). The authors concluded that among 
patients with stable atherothrombosis, NSAID use was 
associated with a higher risk of MI, stroke, and 
hospitalizations for both ischemia and heart failure.  
As already mentioned, in another meta-analysis of 13 
randomized controlled trials assessing the effect of 
NSAIDs on CV events in trials of joint disease and 
Alzheimer's disease, the authors concluded that NSAIDs 
had no significant effect on CV events or death in the joint 
disease trials, but an indication for risk was present in trials 
of Alzheimer's disease.12 They also stated that there was no 
significant adverse or cardioprotective effect of naproxen.  
CYCLOOXYGENASE-2 NONSTEROIDAL ANTI-
INFLAMMATORY DRUGS 
The first observation of NSAID-associated CV risk 
came from the Vioxx Gastrointestinal Outcomes Research 
Study (VIGOR), which demonstrated a fivefold difference 
in the incidence of acute MI between patients treated with 
rofecoxib 50 mg/day and naproxen 1000 mg/day,2 and was 
further corroborated by a meta-analysis of clinical trials of 
celecoxib and rofecoxib.18 In addition, a nested case-
control study sought to establish if risk was enhanced with 
rofecoxib at either high or standard doses compared with 
remote NSAID use or celecoxib use.3 A total of 1,394,764 
people contributed 2,302,029 person years of observation 
time to the study cohort of NSAID users. Patients received 
various NSAIDs, including celecoxib (n=40,405), 
ibuprofen (991,261), naproxen (435,492), and rofecoxib 
(26,748). From this cohort, 8143 cases of serious coronary 
heart disease and 31,496 matched controls were identified. 
Among the cases, 2210 (27.1%) were fatal. Multivariate 
odds ratios versus celecoxib were: for rofecoxib (all 
doses), 1.59 (p=0.015); for rofecoxib <25 mg/day, 1.47 
(p=0·054); and for rofecoxib >25 mg/day, 3.58 (p=0.016). 
For naproxen versus remote NSAID use the odds ratio was 
1.14 (p=0.05). The authors concluded that rofecoxib use 
increases the risk of serious coronary heart disease 
compared with celecoxib use, while naproxen use does not 
protect against serious coronary heart disease.  
Another meta-analysis comprised 7,462 patients who 
received celecoxib (200 - 800 mg/day) for 1,268 patient-
years who were compared with 4,057 patients treated with 
placebo for 585 patient-years, as well as 19,773 patients 
treated with similar dose of celecoxib for 5,651 patient-
years who were compared with 13,990 patients treated 
with nonselective NSAIDs (diclofenac, ibuprofen, 
naproxen, ketoprofen, and loxoprofen) for 4,386 patient-
years.5 The incidence rates of the combined CV events 
were not significantly different between patients treated 
with celecoxib and placebo or between those treated with 
celecoxib and nonselective NSAIDs. Dose of celecoxib, 
the use of aspirin, or the presence of CV risk factors did 
not change these results. The authors concluded that these 
analyses failed to demonstrate an increased CV risk with 
celecoxib relative to placebo and demonstrated a 
comparable rate of CV events with celecoxib treatment 
compared with nonselective NSAIDs. The authors also 
acknowledge a major limitation of their analysis, since all 
but one of the comparator trials did not exceed 1 year of 
patient follow-up.5   
NONSELECTIVE AND SELECTIVE NSAIDs 
A recent Danish study19 examined the risk of bleeding 
and CV events among 61,971 patients (mean age, 68) with 
prior MI taking antithrombotic drugs, who were also 
prescribed a NSAID. The number of deaths during a 
median follow-up of 3.5 years was 18,105 (29.2%). A total 
of 5288 bleeding events (8.5%) and 18,568 CV events 
(30%) occurred. The crude incidence rates of bleeding 
(events per 100 person-years) were 4.2 with concomitant 
NSAID treatment and 2.2 without NSAID treatment, 
whereas the rates of CV events were 11.2 and 8.3. 
Multivariate analysis found increased bleeding (hazard 
ratio-HR, 2.02) and CV risk (HR, 1.40) with NSAID 
treatment compared with no NSAID treatment. An 
increased risk of bleeding and CV events was evident with 
concomitant use of NSAIDs, regardless of antithrombotic 
treatment, types of NSAIDs, or duration of use. The 
authors concluded that among patients receiving 
antithrombotic therapy after MI, the use of NSAIDs was 
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associated with increased risk of bleeding and excess 
thrombotic events, even after short-term treatment.  
In a post-hoc analysis from the INternational Verapamil 
Trandolapril STudy (INVEST),7 which enrolled patients 
with hypertension and coronary artery disease, at a mean 
follow-up of 2.7 years, the primary outcome (all-cause 
death, nonfatal MI or stroke) occurred at a rate of 4.4 
events per 100 patient-years in the chronic NSAID group 
(n=882), vs 3.7 events per 100 patient-years in the non-
chronic NSAID group (n=21,691; 14,408 never users and 
7286 intermittent users) (HR 1.47; P = 0.0003). This was 
due to an increase in CV mortality (HR 2.26; P<0.0001). 
The authors concluded that among hypertensive patients 
with coronary artery disease, chronic self-reported use of 
NSAIDs was associated with an increased risk of adverse 
events during long-term follow-up. 
A recent Danish analysis20 of two cohort studies and 
two case-control studies explored additional (to MI, stroke, 
heart failure, and hypertension) NSAID-associated CV 
risks. The authors examined whether use of non-aspirin 
NSAIDs was associated with risk of MACE after coronary 
stent implantation, risk of venous thromboembolism, risk 
of atrial fibrillation, and 30-day stroke mortality. They 
reported that use of non-aspirin NSAIDs was not 
associated with MACE following coronary stent 
implantation, but was associated with an increased risk of 
venous thromboembolism, atrial fibrillation, and 30-day 
mortality following ischemic stroke, especially when 
therapy with selective COX-2 inhibitors was initiated. 
The MEDAL (Multinational Etoricoxib and Diclofenac 
Arthritis Long Term) program assessed the relative CV 
safety of two long-term anti-inflammatory treatments, 
etoricoxib and diclofenac, in 34,701 patients, 24,913 with 
osteoarthritis and 9,787 with rheumatoid arthritis.21 Over 
an average treatment duration of 18 months, the rates of 
thrombotic CV events in patients on etoricoxib were 
similar to those in patients on diclofenac. Another analysis 
found a continuous linear dose relationship between 
specific diclofenac doses and the risk of a serious GI or CV 
event, thus giving credence to guidelines that recommend 
the use of NSAIDs at the lowest effective dose for the 
shortest duration.22-25   
BALANCING RISKS AND BENEFITS 
NSAID selectivity is a continuous, not a dichotomous, 
variable, and rather a function of dose, while the risk varies 
from drug to drug.23 Diclofenac and celecoxib, for 
example, have almost equal selectivity. However, a COX-
2 inhibitor given at high dose becomes a COX-1 inhibitor. 
Thus, high doses of COX-2 NSAIDs should be avoided. 
Most long-term data indicating increased CV risk are 
derived from trials with selective NSAIDs, but, as 
indicated above, an increase in overall CV risk is not 
confined to COX-2 NSAIDs and may be shared by a 
number of nonselective NSAIDs for which the data appear 
equally worrisome.6, 25  
NSAID-aspirin interaction. Clinical trials and 
observational studies support the hypothesis that 
nonselective NSAIDs interfere with the antiplatelet effects 
of aspirin and block its cardioprotective effects. It has been 
shown that ibuprofen taken 2 hours before an aspirin dose 
may occupy the site during the entire time that aspirin is 
available to the platelet for permanent acetylation. The 
Food and Drug Administration (FDA) has issued a 
MedWatch  that cautioned patients about the potential for 
ibuprofen to interfere with the CV protective effect of low-
dose aspirin.6 The FDA stated that since there are no data 
about the effect of other NSAIDs, until proven otherwise, 
patients should take aspirin 2 hours before taking an 
NSAID. In contrast, selective COX-2 inhibitors do not 
interfere with the actions of aspirin and preserve its ability 
to reduce the risk of MI and stroke in high-risk patients. 
On the other hand, studies to date suggest that aspirin lacks 
a favorable effect on CV risk in patients who take a 
selective COX-2 inhibitor. Thus, based on current data, a 
patient who takes aspirin for secondary prevention should 
not be prescribed a COX-2 inhibitor.  
Hypertensive and CV Risk. The impact of NSAIDs in 
a non-hypertensive patient population is much less than in 
a hypertensive population, especially patients on 
angiotensin-converting enzyme (ACE) inhibitors, 
angiotensin receptor blockers, beta-blockers, and perhaps 
diuretics— but not calcium channel blockers. The 
available evidence suggests that selective and nonselective 
NSAIDs do not increase CV risk in the absence of a 
clinically meaningful increase in blood pressure. 
Among hypertensive patients on drug therapy, NSAIDs 
have a much larger effect in elevating the blood pressure6 
or have harmful effects even when blood pressures appears 
controlled.7 The biggest changes are seen in patients on 
ACE inhibitors and beta blockers, because NSAIDs appear 
to interfere with the action of those drugs. Blood pressure 
control in patients on calcium channel blockers appears to 
be unaffected by NSAIDs. 
The package-insert labeling on the CV risk of NSAIDs 
states, “NSAID may cause an increased risk of serious CV 
thrombotic events, MI, and stroke, which can be fatal. All 
NSAIDs may have a similar risk. This risk may increase 
with duration of use. Patients with CV disease or CV risk 
factors may be at greater risk. NSAID is contraindicated 
for the treatment of perioperative pain in the setting of 
coronary artery bypass graft surgery.” 
A NSAID may promote thrombus formation. It is 
important to differentiate between the effects of traditional 
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NSAIDs and the COX-2s on thrombotic risk and 
hypertension. Both drug classes increase blood pressure 
and if untreated over the long term, this increase in blood 
pressure can contribute to the progression of CV disease, 
as would the hypertension of any etiology. However, the 
events that raised concern about the safety of these 
medications were acute thrombotic events, like MI and 
stroke. However, these events are not the consequence of 
hypertension per se. This pathogenic mechanism is 
consistent with the effects of COX-2 selectivity and dose 
(i.e., more selective, higher doses), increasing baseline CV 
risk, and increased duration of treatment on the incidence 
of acute CV events. Furthermore, NSAIDs make platelets 
more reactive. The thrombotic event is a plaque rupture. 
Taking an NSAID, which inhibits prostacyclin, shifts 
platelet reactivity and increases the likelihood of thrombus 
formation because the inhibitory effect of prostacyclin is 
decreased or lost. It should be noted that with an acute MI, 
the NSAID increases the risk.  
Balancing GI and CV Risk. If a patient has not 
responded or does not choose to undertake initial non-
pharmacological approaches for the arthritic pain, it is 
recommended to start with a drug like acetaminophen, 
which, although not free of risk, may have less identified 
GI and CV risks. However, acetaminophen does have 
some hepatic and renal risk. In most guidelines, 
acetaminophen is a first-line drug.24, 25 Aspirin is not really 
included in the guidelines, beyond low-dose aspirin, 
because the GI toxicity of aspirin beyond low doses is 
higher than that of any of the other NSAIDs. If an NSAID 
is required, the question arises as to which one should be 
prescribed. It is here that risk factors for GI tract bleeding 
become important and probably outweigh CV risk. These 
drugs are more alike in their CV risk than GI risk. In 
patients with higher GI risk, the risk/benefit ratio shifts in 
the direction of the COX-2 inhibitors (Fig. 1). For patients 
already taking low-dose aspirin, the risk/benefit also shifts 
in favor of COX-2s, compared to nonselective NSAIDs, 
with their potential aspirin interaction. It should also be 
noted that Helicobactor pylori eradication reduces the risk 
of GI complications of NSAIDs.26  
Also one should remember that risks with NSAIDs 
include hypertension and edema, but the biggest risk has 
always been GI bleeding. The quoted rate is up to 50,000 
deaths per year related to GI bleeding, with 10,000 
preventable deaths! If one could reduce those in half with 
a strategy of using either a proton pump inhibitor (PPI) 
with a nonselective NSAID or a COX-2 inhibitor, then one 
would have considerably improved morbidity and 
mortality in this patient population. Indeed, 
rheumatologists worry more about complications of the GI 
tract than the heart.  
Thus, GI bleeding is a major concern for patients taking 
NSAIDs. However, some clinicians are concerned that the 
GI safety advantage of COX-2-selective drugs is offset by 
an increase in CV risk. The GI safety advantage of 50 mg 
of rofecoxib compared to 500 mg bid naproxen in the 
VIGOR trial was offset by a similar increase in CV events. 
A similar increase in CV events was not seen in the CLASS 
(Celecoxib Long-Term Arthritis Safety Study) trial in 
patients using 800 mg of celecoxib compared to usual 
doses of ibuprofen or diclofenac.27 Both these trials were 
powered for GI events, and unfortunately, there are no 
published randomized controlled trials with COX-2 
inhibitors powered for CV end points. In a large 
observational study of approximately 1.4 million patients 
in the California Kaiser-Permanente system, use of more 
than 25 mg of rofecoxib was associated with an increased 
CV risk of about 300%, approximately the equivalent of 
the CV risk of cigarette smoking.3 However, a similar risk 
was not seen in this study with lower doses of rofecoxib 
and there was no observed increase in risk with celecoxib 
compared to nonusers of NSAIDs. A major discussion in 
rheumatology apparently is whether to prescribe a COX-2 
inhibitor in patients with increased GI risk or a non-
selective NSAID plus a PPI and whether patients will be 
compliant. In the absence of a tablet combining a PPI plus 
a NSAID, a COX-2 inhibitor has an advantage based on 
patient compliance with use of a single drug instead of two. 
The risk of GI bleeding on an NSAID plus a PPI regimen 
is about the same as a COX-2 inhibitor alone. In elderly 
patients with a prior history of GI bleeding who are on low 
dose aspirin, celecoxib plus a PPI is another alternative. 
NSAID Agent Selection. It is important that 
cardiologists, who are not among those physicians 
frequently prescribing NSAIDs, have a particular 
responsibility to be apprised of current information and 
data relevant to the CV risks of NSAIDs, especially when 
these agents are administered to patients receiving low-
dose aspirin for cardioprotection.28 Moreover, every 
physician prescribing these agents should carefully weigh 
the benefits and risks of the use of NSAIDs from a CV and 
GI perspective by thoughtfully synthesizing the evidence 
for CV safety and prudently making decisions for 
individual patients (Fig. 1).17  
According with a recent meta-analysis of data on the 
relative risk of CV events with individual NSAIDs listed 
on the Essential Medicines Lists (EMLs) of several 
countries, 3 drugs (rofecoxib, diclofenac, etoricoxib) had 
consistently highest CV risk compared with nonuse.9 
Naproxen was associated with a low risk. Diclofenac was 
listed on 74 national EMLs, naproxen on 27. Rofecoxib 
use was not documented in any country, since its 
withdrawal. Diclofenac and etoricoxib accounted for one-
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third of total NSAID usage. Diclofenac was by far the most 
commonly used NSAID. The authors concluded that 
listing of NSAIDs on national EMLs should take into 
account the associated CV risk, and since diclofenac has a 
risk very similar to rofecoxib, it should be withdrawn from 
the market and removed from EMLs.  
 Figure 1. A suggested algorithm for use of NSAIDs. COX = 
cyclooxygenase; CV = cardiovascular; GI = gastrointestinal; 
Mod = moderate; NS = non-selective; NSAID = non-steroidal 
anti-inflammatory drug; PPI = proton pump inhibitor.  
* The American Heart Association25 suggests a stepped-care 
approach to pharmacological therapy for the management of 
musculoskeletal symptoms in patients with known CV disease 
or risk factors, focusing on agents with the lowest reported risk 
of CV events (acetaminophen, aspirin, tramadol, narcotic 
analgesics, nonacetylated salicylates) and then progressing 
toward other agents associated with increasing levels of CV risk, 
that is, non–COX-2–selective NSAIDs → NSAIDs with some 
COX-2 activity → COX-2–selective NSAIDs.   
** Ibuprofen is contraindicated when on aspirin.  
N.B.: NSAIDs should be taken at the lowest effective dose for 
the shortest possible time to minimize both CV and GI risks.   
The loss of prostaglandins has important homeostatic 
CV effects. When a selective or nonselective NSAID is 
given, a variety of prostaglandins are inhibited in the joint 
tissues, in the kidneys, and in blood vessels in a dose-
dependent manner. When high doses of certain drugs are 
given to susceptible patients, CV risk can increase. 
Because risk has been established for many selective 
COX-2 inhibitors but not for most nonselective NSAIDs, 
many clinicians prescribe a nonselective NSAID 
preferentially to patients who have 1 or more cardiac risk 
factors. However, there are no data suggesting that most 
nonselective NSAIDs carry less risk than most selective 
COX-2 inhibitors, regardless whether there is underlying 
hypertension or dyslipidemia. For patients with multiple 
underlying cardiac risk factors receiving low-dose aspirin, 
the evidence indicates that clinicians should prescribe a 
selective COX-2 inhibitor. In high-risk patients, it is 
critical to preserve the cardioprotective effects of aspirin, 
and this can be achieved only with a selective COX-2 
inhibitor. Furthermore, there appears to be a dose effect of 
celecoxib in terms of CV risk, so at reasonably low doses, 
it may be relatively safe. 
Thus, if an anti-inflammatory drug is needed for the 
treatment of arthritis, the current evidence suggests that 
either naproxen or a low dose of celecoxib (200 mg daily) 
has no measurable CV risk. The 2 drugs that appear to 
carry the highest CV risk are rofecoxib (selective COX-2 
inhibitor) and diclofenac (nonselective NSAID). The 
evidence with diclofenac is particularly worrisome. 
Diclofenac causes increased blood pressure and increased 
CV risk in both clinical trials and epidemiological studies. 
Current recommendations also indicate that NSAIDs 
should be taken at the lowest effective dose for the shortest 
possible time to minimize both CV and GI risks.22, 23 
Caution should be particularly exercised in prescribing 
COX-1 and 2 inhibitors for musculoskeletal disorders in 
patients who already suffer from GI or CV conditions.  
Most recently, the Pharmacovigilance Risk Assessment 
Committee (PRAC) of the European Medicines Agency 
(EMA) issued a warning of an increased risk of CV events 
in patients who take high doses of ibuprofen. The 
Committee states that there is a small increase in the risk 
of MI and stroke with ibuprofen when taken at doses of 
2400 mg/day or higher (http://www.ema.europa.eu/ema/ 
index.jsp?curl=pages/news_and_events/news/2015/04/news_de
tail_002306.jsp&mid=WC0b01ac058004d5c1). The risk, 
according to the committee, is similar to the risk observed 
with other NSAIDs, such as COX-2 inhibitors and 
diclofenac. However, the EMA had earlier stated that there 
was a consistent but small increase in the risk of CV side 
effects with diclofenac compared with other NSAIDs 
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_an
d_events/news/2013/06/news_detail_001830.jsp&mid=WC0b0
1ac058001d126).  
A very large prospective randomized NSAID study will 
be reporting long-awaited CV safety results in the next 
year.29 The PRECISION (Prospective Randomized 
Evaluation of Celecoxib Integrated Safety vs Ibuprofen or 
Naproxen) trial has randomized approximately 24,000 
patients with symptomatic rheumatoid arthritis or 
osteoarthritis and at high risk for or with established CV 
disease to 1 of 3 available NSAIDs (celecoxib, ibuprofen 
or naproxen). 
From the above discussion, it becomes clear that we are 
in dire need to develop new and effective NSAID 
formulations to minimize the safety and tolerability 
concerns associated with currently available NSAIDs, yet 
maintain efficacy in management of inflammation and 
pain.30        
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Low GI Risk  Mod/High GI Risk  Low GI Risk ** Mod/High GI Risk
 
 
 
Non-selective NSAID     COX-2 NSAID / or  Naproxen     Low-dose Celecoxib+PPI
   Non-selective NSAID + PPI Other NS NSAID Naproxene + PPI 
       Celecoxib 
       (+PPI if on aspirin)  
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